Sensei Biotherapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-03-04.
Sensei Biotherapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on March 4, 2026. The filing reports $348.91M sold. Its industry group is Biotechnology. It names Christopher Gerry (Executive Officer, Director), Josiah Craver (Executive Officer), Tom Ricks (Director) (SEC Form D, March 4, 2026).
Sell to companies like Sensei Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-03-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Sensei Biotherapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Sensei Biotherapeutics, Inc., from the filings we hold.
Leerink Partners received sales compensation on this raise and on 5 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Maryland, filed in March 2026, largest first.
Get an email when Sensei Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Sensei Biotherapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Sensei Biotherapeutics, Inc. →Get the full cited report on Sensei Biotherapeutics, Inc.
What the filing shows about Sensei Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sensei Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Sensei Biotherapeutics, Inc. See pricing
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $348.91M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Christopher Gerry is named as Executive Officer and Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Josiah Craver is named as Executive Officer on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Tom Ricks is named as Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Anand Parikh is named as Executive Officer and Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Phillip Donenberg is named as Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Bob Holmen is named as Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
Kristian Humer is named as Director on the Form D that Sensei Biotherapeutics, Inc. filed with the SEC on 4 March 2026, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2026-03-04 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Sensei Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sensei Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sensei Biotherapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Sensei Biotherapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Sensei Biotherapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Sensei Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Washington, DC
https://mentionfox.com/funding/sensei-biotherapeutics-inc-form-d-26000001